[{"address1": "4710 Bellaire Boulevard", "address2": "Suite 210", "city": "Bellaire", "state": "TX", "zip": "77401", "country": "United States", "phone": "832 742 1357", "website": "https://www.biopathholdings.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas P. Morris", "age": 68, "title": "Co-Founder, Chairman, Director of Investor Relations & Secretary", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 76731, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Hickey M.B.A.", "title": "VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Price MBA", "title": "Senior Vice President of Finance, Accounting & Administration", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D.", "title": "Senior Vice President of Research, Development & Clinical Design", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.14, "open": 0.1302, "dayLow": 0.1302, "dayHigh": 0.1302, "regularMarketPreviousClose": 0.14, "regularMarketOpen": 0.1302, "regularMarketDayLow": 0.1302, "regularMarketDayHigh": 0.1302, "payoutRatio": 0.0, "trailingPE": 0.36111107, "forwardPE": -0.032178216, "volume": 997, "regularMarketVolume": 997, "averageVolume": 38538, "averageVolume10days": 25310, "averageDailyVolume10Day": 25310, "bid": 0.1302, "ask": 0.145, "bidSize": 32200, "askSize": 9616, "marketCap": 1080027, "fiftyTwoWeekLow": 0.12, "fiftyTwoWeekHigh": 3.39, "fiftyDayAverage": 0.1664, "twoHundredDayAverage": 0.43015, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "sharesOutstanding": 8307890, "sharesShort": 79346, "sharesShortPriorMonth": 249950, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0138, "heldPercentInsiders": 0.0002, "heldPercentInstitutions": 0.05252, "shortRatio": 0.43, "shortPercentOfFloat": 0.0138, "impliedSharesOutstanding": 8307900, "bookValue": 0.027, "priceToBook": 4.8148146, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "trailingEps": 0.36, "forwardEps": -4.04, "lastSplitFactor": "1:20", "lastSplitDate": 1708646400, "52WeekChange": -0.91333336, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 0.13, "targetHighPrice": 2.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.0, "targetMedianPrice": 2.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "BPTH", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "corporateActions": [], "shortName": "Bio-Path Holdings, Inc.", "longName": "Bio-Path Holdings, Inc.", "regularMarketTime": 1755216000, "exchange": "OQB", "messageBoardId": "finmb_37512626", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -7.1428604, "regularMarketPrice": 0.13, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1204641000000, "regularMarketChange": -0.010000005, "regularMarketDayRange": "0.1302 - 0.1302", "fullExchangeName": "OTC Markets OTCQB", "averageDailyVolume3Month": 38538, "fiftyTwoWeekLowChange": 0.009999998, "fiftyTwoWeekLowChangePercent": 0.08333332, "fiftyTwoWeekRange": "0.12 - 3.39", "fiftyTwoWeekHighChange": -3.2600002, "fiftyTwoWeekHighChangePercent": -0.961652, "fiftyTwoWeekChangePercent": -91.333336, "dividendDate": 1547769600, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "earningsCallTimestampStart": 1731677400, "earningsCallTimestampEnd": 1731677400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.36, "epsForward": -4.04, "epsCurrentYear": -1.59, "priceEpsCurrentYear": -0.081761, "fiftyDayAverageChange": -0.036400005, "fiftyDayAverageChangePercent": -0.21875003, "twoHundredDayAverageChange": -0.30015, "twoHundredDayAverageChangePercent": -0.69777983, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "marketState": "CLOSED", "hasPrePostMarketData": false, "displayName": "Bio-Path", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]